Literature DB >> 12406440

Pathology of steatohepatitis.

Elizabeth M Brunt1, Dina G Tiniakos.   

Abstract

Pathologists have long been involved in clinical diagnosis and investigative studies of various forms of liver disease, including alcoholic liver disease. The concept that progressive fatty liver disease may result from causes other than alcohol toxicity can be noted in the literature. However, acceptance of this as a bona fide form of liver disease has been credited to an in-depth study published in 1980 of patients gathered from cases in the files of the pathology department of the Mayo Clinic in whom liver biopsies showed histological similarities to alcoholic steatohepatitis, but for whom clinical evidence of alcohol use was absent. Subsequent studies of the natural history and pathogenesis of non-alcoholic steatohepatitis have relied on detailed histopathological correlations. This chapter will elucidate the constellation of microscopic findings, the issues of concern for pathological evaluation and the knowledge to date of their significance in various forms of fatty liver disease.

Entities:  

Mesh:

Year:  2002        PMID: 12406440     DOI: 10.1053/bega.2002.0326

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  13 in total

1.  Hepatic fat assessment using advanced Magnetic Resonance Imaging.

Authors:  Yong Pang; Baiying Yu; Xiaoliang Zhang
Journal:  Quant Imaging Med Surg       Date:  2012-09

Review 2.  Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease.

Authors:  Andrea Tannapfel; Helmut Denk; Hans-Peter Dienes; Cord Langner; Peter Schirmacher; Michael Trauner; Berenike Flott-Rahmel
Journal:  Virchows Arch       Date:  2011-03-26       Impact factor: 4.064

3.  Vulnerability of experimentally induced fatty liver to heat stress in rats.

Authors:  Hiromasa Inoue; Naomi Sameshima; Tomomi Ishida; Akiko Tsuji; Keiko Kudo; Noriaki Ikeda
Journal:  J Gastroenterol       Date:  2006-01       Impact factor: 7.527

Review 4.  [Steatohepatitis after chemotherapy for colorectal liver metastases (CASH)].

Authors:  A Tannapfel; A Reinacher-Schick; B Flott-Rahmel
Journal:  Pathologe       Date:  2011-07       Impact factor: 1.011

Review 5.  Morphological, dynamic and functional characteristics of liver pseudolesions and benign lesions.

Authors:  Matteo Renzulli; Nicolò Brandi; Giulia Argalia; Stefano Brocchi; Andrea Farolfi; Stefano Fanti; Rita Golfieri
Journal:  Radiol Med       Date:  2022-01-13       Impact factor: 3.469

6.  Effects of different therapeutic methods and typical recipes of Chinese medicine on activation of c-Jun N-terminal kinase in kupffer cells of rats with fatty liver disease.

Authors:  Qin-He Yang; Si-Ping Hu; Yu-Pei Zhang; Huan-Huan Ping; Huan-Wen Yang; Tong-Yan Chen; Hai-Tao Liu
Journal:  Chin J Integr Med       Date:  2012-09-11       Impact factor: 1.978

7.  Spinal cord injury causes chronic liver pathology in rats.

Authors:  Andrew D Sauerbeck; J Lukas Laws; Veera V R Bandaru; Phillip G Popovich; Norman J Haughey; Dana M McTigue
Journal:  J Neurotrauma       Date:  2014-10-21       Impact factor: 5.269

8.  Bax inhibition protects against free fatty acid-induced lysosomal permeabilization.

Authors:  Ariel E Feldstein; Nathan W Werneburg; Zhengzheng Li; Steven F Bronk; Gregory J Gores
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2006-02-16       Impact factor: 4.052

9.  Increased hepatocellular uptake of long chain fatty acids occurs by different mechanisms in fatty livers due to obesity or excess ethanol use, contributing to development of steatohepatitis in both settings.

Authors:  Paul D Berk; Shengli Zhou; Michael W Bradbury
Journal:  Trans Am Clin Climatol Assoc       Date:  2005

Review 10.  [Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Grade 2 consensus-based guidelines].

Authors:  A Tannapfel; H Denk; H P Dienes; C Langner; P Schirmacher; M Trauner; B Flott-Rahmel
Journal:  Pathologe       Date:  2010-05       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.